

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Rapid vaccination and early reactive partial lockdown will minimize deaths from emerging highly contagious SARS-CoV-2 variants

Daniel B Reeves¹†, Chloe Bracis²†, David A. Swan¹, Mia Moore¹, Dobromir Dimitrov^{1,3}††, Joshua T. Schiffer^{1,4,5}††

¹Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA

²Université Grenoble Alpes, TIMC-IMAG / BCM, 38000, Grenoble, France

³Department of Applied Mathematics, University of Washington, Seattle, WA, USA

⁴Clinical Research Division, Fred Hutchinson Cancer Research Center; Seattle, WA, USA

⁵Department of Medicine, University of Washington, Seattle, WA, USA

†,†† = equal contribution

26 **Abstract.** The goals of SARS-CoV-2 vaccination programs are to maximally reduce cases and
27 deaths, and to limit the amount of time required under lockdown. Using a mathematical model
28 calibrated to data from King County Washington but generalizable across states, we simulated
29 multiple scenarios with different vaccine efficacy profiles, vaccination rates, and case thresholds
30 for triggering and relaxing partial lockdowns. We assumed that a contagious variant is currently
31 present at low levels. In all scenarios, it rapidly becomes dominant by early summer. Low case
32 thresholds for triggering partial lockdowns during current and future waves of infection strongly
33 predict lower total numbers of COVID-19 infections, hospitalizations and deaths in 2021.
34 However, in regions with relatively higher current seroprevalence, there is a predicted delay in
35 onset of a subsequent surge in new variant infections. For all vaccine efficacy profiles, increasing
36 vaccination rate lowers the total number of infections and deaths, as well as the total number of
37 days under partial lockdown. Due to variable current estimates of emerging variant
38 infectiousness, vaccine efficacy against these variants, vaccine refusal, and future adherence to
39 masking and physical distancing, we project considerable uncertainty regarding the timing and
40 intensity of subsequent waves of infection. Nevertheless, under all plausible scenarios, rapid
41 vaccination and early implementation of partial lockdown are the two most critical variables to
42 save the greatest number of lives.

43 **Introduction**

44 The COVID-19 pandemic is a profound tragedy that has resulted in widespread death and
45 high morbidity.¹ Its social impact has also been devastating with recurrent lockdown resulting in
46 economic loss and psychological damage, particularly among children who are being deprived of
47 in-person schooling.²⁻⁴

48 Accordingly, recently initiated COVID-19 vaccination programs have public health and
49 societal goals. Vaccine allocation strategies are intended to prevent the largest numbers of
50 cumulative deaths, as well as high peaks in hospitalizations to avoid collapse of healthcare
51 systems.⁵ Because a moderate proportion of infected people develops debilitating long-term
52 symptoms, limiting cumulative case numbers is also a priority.⁶

53 Another goal is to support conditions allowing sustained safe reopening of schools,
54 businesses, and public events.⁷ One metric for assessing this is the number of days during which
55 partial lockdown will be necessary during 2021. Prior to vaccination implementation, numerous
56 strategies existed to prevent surges in cases and subsequent lockdowns including testing and
57 tracing,⁸ masking,^{9,10} and limiting crowd size in indoor spaces.¹¹ While these efforts undoubtedly
58 had positive effects, they were not sufficient to prevent three recurrent waves of infection in the
59 United States.¹² The first two waves occurred in early spring and mid-summer with the intensity
60 of cases varying substantially among states. The ongoing third wave is more generalized leading
61 to overburdened hospitals and a huge surge in deaths in multiple states.¹³

62 A further concern is the emergence of more infectious viral variants across the globe with
63 relevant examples in England,¹⁴ Brazil,¹⁵ and South Africa.¹⁶ The B.1.1.7 variant is estimated to
64 be considerably more contagious and is overwhelming many health care systems in the United
65 Kingdom.¹⁷ B.1.1.7 has also been identified in numerous locations across the United States.

66 While its prevalence is currently low, B.1.1.7 and potentially other new variants are predicted to
67 predominate in upcoming months.¹⁸

68 The precise impact of new SARS-CoV-2 variants in the face of improving non-
69 pharmaceutical preventative measures has yet to be determined. More widespread use of highly
70 efficacious N95 masks, particularly among people who work in potential super-spreader
71 environments, could limit SARS-CoV-2 spread more effectively than current masking
72 approaches.¹⁹ Widespread availability of inexpensive and rapid tests, paired with effective
73 contact tracing, could also limit incident infections.²⁰ However, it remains uncertain whether
74 these additions will be sufficient to prevent exponential growth of the B.1.1.7 variant which
75 increases the effective reproductive number by 56% (range: 50-74%).²¹

76 During 2020, physical distancing mandates, or partial lockdowns, were often necessary to
77 curb unchecked local epidemics.²² The effectiveness of partial lockdowns was evident in the
78 northeast United States and Europe during the spring of 2020, and more recently in multiple
79 northern plains states where incident cases contracted after a very high peak.¹³ In the UK and
80 Ireland, the B.1.1.7 variant emerged during lockdown necessitating a stricter lockdown in
81 January, after which cases have declined.²³ Unfortunately, partial lockdown measures come at
82 great societal cost, including business and school closures that disproportionately impact
83 socioeconomically disadvantaged regions and communities of color. A major goal of any
84 vaccination strategy should be to limit the duration and intensity of partial lockdown in 2021.

85 Existing mathematical models have considered optimal allocation of SARS-CoV-2
86 vaccines,²⁴⁻²⁸ one versus two-dose strategies,²⁹ and the impact of vaccine effects against
87 infectiousness.³⁰⁻³² Here, using a model calibrated to data from King County Washington,³³ we
88 consider the complexities of vaccine implementation during the ongoing intense third wave of

89 SARS-CoV-2 infections, as well as the likely future emergence of more contagious variants. Our
90 goal is to understand which variables have the greatest effect on infections and deaths, in order to
91 limit them while also decreasing total time under lockdown. The model also allows for
92 projections in other states that had lower or higher cumulative incidence at the time when their
93 vaccination programs initiated.

94 **Results**

95

96 **King County mathematical model.** We developed an epidemiological model of SARS-CoV-2
97 spread in King County Washington (**Sup fig 1a**).^{30,31,33} As described elsewhere, we calibrated the
98 model to diagnosed cases, hospitalizations, and deaths, all stratified according to age cohort, to
99 capture the epidemic pre-vaccination through early November.³¹ A mathematical description of
100 the model is presented in the **Methods** and complete mathematical details are found in the
101 **Supplementary Information.**

102 The model follows three sequential waves of infections with peaks in March, August, and
103 December of 2020. Each wave has different peak incidence and age-cohort predominance and
104 occurred due to an antecedent increase in the effective reproductive number (R_e).¹⁹ Without a
105 vaccine, R_e is governed by the frequency of exposure contacts between susceptible and infected
106 individuals. A key feature of our model is a time-varying, age-stratified vector (σ_t) governing
107 social distancing (non-pharmaceutical interventions) including reduced contacts through personal
108 choices and/or mandated partial lockdowns, as well as reductions in exposure contacts due to
109 mask wearing or physical distancing. The components of the vector σ_t vary from 0, indicating
110 pre-pandemic levels of societal interactivity and no masking, to 1, indicating complete lockdown
111 with no interactions (**Supp Fig 1b**). For data prior to November 2020, we estimated σ_t for each
112 age group by calibrating monthly to cases, hospitalization and deaths.

113 In 2021, we project that σ_t will continue to vary according to government policy and
114 public behavior. We include several parameters to reflect this uncertainty. The first is the case
115 threshold to trigger partial lockdown (C_{max}). If two-week number of diagnosed cases per
116 100,000 people rises above C_{max} , a “partial-lockdown” ($\sigma_t \rightarrow \sigma_{PL}$) is mandated (**Supp Fig 1b**).

117 Partial lockdown is defined by an enforced social distancing of $\sigma_{PL}=0.6$ in the 3 non-elderly age
118 cohorts and $\sigma_{PL}=0.8$ in the elderly cohort (≥ 70 years). Values of σ_{PL} and C_{max} were selected
119 based on previous partial lockdowns implemented in Washington State during 2020.³¹ We
120 explore a wide range for C_{max} in our analysis between 200 and 650, both to reflect
121 heterogeneity in severity of the ongoing third wave across states which occurred due to
122 implementing partial lockdowns at varying thresholds, and to represent future uncertainty.

123 Similarly, C_{min} is the case threshold (two-week number of diagnosed cases per 100,000
124 people) which triggers reopening during which σ_t gradually decreases (at 10% every two weeks)
125 from σ_{PL} to σ_{min} in the 3 younger cohorts ($\sigma_{min}+0.2$ in seniors). We test 20, 60 and 100 as
126 possible values for C_{min} . Unless otherwise noted, the level of social distancing after a period of
127 societal reopening (σ_{min}) is maintained at 0.2 to capture persistent behaviors such as masking,
128 working from home and avoidance of large social gatherings, which inherently limit the number
129 of interpersonal contacts relative to pre-pandemic levels.

130

131 ***Vaccination scenarios.*** Three variables measure vaccine efficacy, including protection against
132 infection (VE_{SUSC}), against symptoms given infection despite vaccination (VE_{SYMP}), and against
133 secondary transmission upon breakthrough infection (VE_{INF}).³⁴ Each of these vaccine efficacies
134 theoretically ranges from 0-100% (0-1 in our model). Vaccine efficacy against symptomatic
135 disease (VE_{DIS}), which represents a combination of VE_{SUSC} and VE_{SYMP} , is usually measured in
136 clinical trials and was estimated at 0.95 for the Pfizer and Moderna licensed vaccines, with
137 unknown contribution by VE_{SUSC} or VE_{SYMP} .^{35,36} VE_{INF} could lower secondary transmission
138 considerably if VE_{SUSC} is low, but its values has also not been measured.³¹ Moreover, the
139 efficacy of the Pfizer and Moderna vaccines against new variants remain unknown. The efficacy

140 of the Novavax and Johnson and Johnson products were 90% and 69% against the consensus
141 variant but were less effective against the South Africa B.1351 lineage.^{37,38} We therefore
142 consider low (0.1), medium (0.5) and high (0.9) values for each of the vaccine efficacies.

143 A final variable is the vaccination rate, r . We use a range of possible rates intended to
144 capture national goals (~3400 people vaccinated per day⁷) and more aggressive state level goals
145 (~8000 people vaccinated per day³⁹) extrapolated to King County. Under all scenarios, we
146 assume current local policy prioritizing seniors by allocating 80% of initial vaccines doses to the
147 elderly cohort until the maximum coverage of 80% among this cohort is reached (**Supp Fig 1c**).

148

149 **Sensitivity analysis.** We performed a global sensitivity analysis under a full factorial design of
150 six input variables (**Table 1**), including two of the described parameters governing social
151 distancing (C_{max} , C_{min}), the three parameters describing vaccine efficacy (VE_{SUSC} , VE_{SYMP} , and
152 VE_{INF}), and vaccination rollout rate r , resulting in 3888 vaccination implementation scenarios.

153 We sought to determine which variables carried the most significant impact on COVID-19
154 related outcomes during 2021 including peak and cumulative infections, diagnosed cases,
155 hospitalization and deaths, as well as total days under partial lockdown (defined by $\sigma_t=0.6$ in 3
156 younger cohorts and $\sigma_t=0.8$ in the elderly) and average value for σ_t during 2021. We calculated
157 Spearman's rank-order correlation, a nonparametric measure assuming monotonicity but not
158 linearity, among outcomes as well as between outcomes and variables.

159

160 **Viral variant assumptions.** The SARS-CoV-2 variant B.1.1.7 is widespread in the United
161 Kingdom and has an estimated increase in infectivity of 56% relative to current predominant
162 circulating variants in the US.²¹ On January 23, 2021, the first two cases of the B.1.1.7 variant

163 were detected in nearby Snohomish County WA and are estimated to be ~1/500 of sequenced
164 samples from a random selection of statewide viruses (Pavitra Roychoudhury, personal
165 communication).⁴⁰ The B.1.1.7 variant is present in multiple other states and widespread cryptic
166 transmission is highly likely. In all simulations presented in the manuscript, we assume two
167 variants, the current circulating consensus and B.1.1.7, which we introduce into the state at a
168 constant rate of five per day beginning January 1, 2021. We also explore scenarios which include
169 plausible bounds of enhanced infectivity (35% and 75% increase), different rates of introduction
170 of the variant into King County (0, 2.5, 5 and 10 per day) and different minimum values social
171 distancing σ_{min} (0.1 and 0.3).

172

173 ***High correlation between numbers of infections, hospitalizations and deaths among***
174 ***vaccination scenarios.*** Various health-related outcomes may be used to assess the success of
175 vaccine distribution including numbers of infected people, diagnosed cases, hospitalizations, and
176 deaths. For each outcome, cumulative totals, totals since vaccination initiation, and peak daily
177 numbers are relevant. Across all simulated scenarios, all health-related outcomes were strongly
178 positively correlated (**Sup fig 2a, 3**). It is therefore unlikely that certain health benefits will be
179 accrued at the expense of others.

180


181 ***Slight negative correlation between health-related outcomes and total days under partial***
182 ***lockdown among vaccination scenarios.*** We next considered outcomes that would have societal
183 benefit. Total number of days under partial lockdown correlated negatively with infections and
184 deaths, signifying that vaccine implementation scenarios which most effectively prevent
185 infections and deaths may require longer durations under partial lockdown (**Sup fig 2a, 3**). The

186 average value of social distancing ($\langle \sigma_t \rangle$) during vaccine rollout did not correlate with health-
187 related outcomes (**Sup fig 2a, 3**). This result indicates that complex locally specific
188 epidemiological dynamics govern the relationship between vaccination and social distancing
189 requirements.

190

191 ***Reduction in COVID-19 infections and deaths due to a low case threshold for triggering***
192 ***partial lockdown.*** The case threshold for triggering partial lockdown (C_{max}) correlated with all
193 outcomes related to infections, hospitalizations and deaths (**Fig 1a**): assuming a vaccine with
194 high efficacy against infection ($VE_{SUSC}=90\%$, $VE_{SYMP}=10\%$, $VE_{INF}=10\%$) and with national
195 target vaccination rates (3500 per day), a low case threshold for triggering partial lockdown
196 ($C_{max} = 200$) would substantially limit number of diagnosed cases, infections, hospitalizations
197 and deaths associated with the current third wave (**Fig 1b, blue line**).

198 However, due to smaller numbers of infections accumulated during the third wave
199 resulting in a larger proportion of people remaining susceptible to infection, low C_{max} is
200 projected to be associated with more rapid emergence of a fourth epidemic wave in May 2021,
201 necessitating further partial lockdowns (**Fig 1b, blue line**). Cumulative infections and deaths are
202 projected to reach 584,311 (27%) and 1524 (0.07%) by 2022. Peak hospitalizations and deaths
203 are expected to be lower during the fourth wave due to early vaccination of the elderly (**Fig 1b**).



204
205
206
207
208
209
210
211
212
213
214
215
216
217

Figure 1. Lowering case threshold for partial lockdown minimizes infections, hospitalizations and deaths but increases total numbers of days under partial lockdown. **a.** Spearman correlations for input variables including case thresholds for triggering (C_{max}) and releasing (C_{min}) partial lockdown. Lowering C_{max} reduces infections, hospitalizations and deaths, but increases total days at maximal social distancing. C_{min} has much weaker effects on outcomes. **b.** Impact of varying case threshold for triggering lockdown on relevant outcomes. Vaccination rate is assumed to be 3500 per day with $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ / $VE_{INF}=10\%$, $C_{min}=25$ cases per 100,000 (2-week average) and $\sigma_{min}=0.2$. New variants are present as of January 1 and introduced into the county at a rate of 5 per day. **c.** Equivalent results assuming no new variant. Black dashed vertical line is the end of model calibration. Orange dashed vertical line is the day of vaccine initiation. **d.** Proportion of infections in **b.** due to new variants.

218
219 The scenario associated with $C_{max}=350$ (**Fig 1b, orange line**) closely reflects current
220 conditions in King County with similar magnitude and timing of peak diagnosed cases,
221 hospitalizations and deaths during the third wave.⁴¹ Under this assumption, a fourth wave of
222 B.1.1.7 cases is projected in July with a partial lockdown required to stem a surge in infections.
223 Total infections and deaths are projected at 689,057 (31%) and 1806 (0.08%) through 2021.

224 At high $C_{max}=650$, a prolonged, severe third wave is projected through April 2021
225 leading to 743,578 (34%) of the population infected and 2077 (0.09%) cumulative deaths by
226 2022 (**Fig 1b, red line**). Peak per capita diagnosed infections are comparable to third waves in
227 northern plains states that instituted slower lockdowns during recent months.¹³ Because
228 vaccination occurs in the context of fewer susceptible people, partial herd immunity is projected
229 and a delayed and blunted fourth wave is predicted, despite the predominance of the B.1.1.7
230 variant (**Fig 1b**).

231 When we remove “no-lockdown” scenarios with $C_{max}=650$ cases per day and thereby
232 assume reactive partial lockdown to high prevalence of local cases, the negative correlation
233 between health-related and societal outcomes across all scenarios disappears. Therefore,
234 reduction in infections and deaths can be prioritized without leading to more days under partial
235 lockdown (**Sup fig 2b**).

236 We finally measure the time difference between $C_{max}=200$ and 350, 350 and 500, and
237 500 and 650, to be approximately 2 weeks. Therefore, decisions to institute partial lockdown that
238 are delayed even slightly may substantially increase infections and deaths.


239

240 ***More rapid predominance of new contagious variants in low prevalence regions.*** Under all
241 C_{max} scenarios, the B.1.1.7 variant is projected to account for a majority of cases during the
242 fourth wave of cases (**Fig 1d**). However, it predominates later in states that have endured a
243 severe third wave relative to states with current lower SARS-CoV-2 prevalence (**Fig 1d**).

244
245 ***No fourth wave of infection in the absence of new contagious variants.*** We performed
246 equivalent analyses but assumed no introduction of variant B.1.1.7 into the population.
247 Assuming a vaccine with high efficacy against infection ($VE_{SUSC}=90\%$, $VE_{SYMP}=10\%$,
248 $VE_{INF}=10\%$) and national target vaccination rates (3500 per day) a fourth wave is projected to be
249 mild or absent, and to not require further partial lockdown, even when the lowest threshold C_{max}
250 is applied. In this scenario, cumulative incidence of infection by the end of 2021 is considerably
251 lower and determined only by the extent of the third wave (**Fig 1c**). Under King County
252 conditions (**Fig 1c, orange line**), we project cumulative infections and deaths to be 398,608
253 (18%) and 1512 (0.07%) the end of 2021.

254
255 ***No difference in the magnitude of the fourth wave of COVID-19 infections and death due to***
256 ***changes in case threshold for relaxing partial lockdowns.*** C_{min} had limited influence on
257 infections, hospitalizations and deaths in 2021 (**Fig 1a**). Lowering C_{min} did delay onset of the 4th
258 wave and the need for partial lockdown by approximately a month (not shown). This delay may
259 prove valuable if vaccination rates increase dramatically during the spring and summer.

260



261
 262 **Figure 2. Increasing vaccination rate minimizes infections, hospitalizations and deaths, as**
 263 **well as total numbers of days under lockdown. a.** Spearman correlations for input variables
 264 related to vaccination rate and efficacy. Increasing vaccination rate reduces infections,
 265 hospitalizations and deaths, and time under partial lockdown. Increasing vaccine efficacy against
 266 infection (VE_{SUSC}) results in uniform benefit for all health-related outcomes and slight reduction
 267 in days at maximal social distancing. Increasing vaccine efficacy against symptoms given
 268 infection (VE_{SYMP}) results in decreases in hospitalizations and deaths. Increasing vaccine
 269 efficacy against infectivity given infection (VE_{INF}) results in slight reduction in numbers of
 270 diagnosed cases and infections. **b-e.** Impact of vaccination rate on relevant outcomes assuming
 271 different efficacy. **b.** $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ / $VE_{INF}=10\%$, **c.** $VE_{SUSC}=50\%$ / $VE_{SYMP}=10\%$
 272 / $VE_{INF}=10\%$, **d.** $VE_{SUSC}=10\%$ / $VE_{SYMP}=90\%$ / $VE_{INF}=10\%$, **e.** $VE_{SUSC}=10\%$ / $VE_{SYMP}=50\%$ /
 273 $VE_{INF}=10\%$. All simulations $C_{max}=350$ cases per 100,000 (2-week average), $C_{min}=25$ cases per
 274 100,000 (2-week average) and $\sigma_{min}=0.2$. Black dashed vertical line is the end of model
 275 calibration. Orange dashed vertical line is the time at which vaccination is initiated. **f.** Proportion
 276 of prevalent infections in **b.** due to new variants.
 277

278 **Reduction in COVID-19 cases and deaths, and days under partial lockdown due to high**
279 **vaccination rate.** Across all scenarios, vaccination rate had a strong negative correlation with
280 infections, hospitalizations and death, as well as days at maximal social distancing (**Fig 2a**).
281 Given a vaccine with strong preventative efficacy ($VE_{SUSC}=90\%$, $VE_{SYMP}=10\%$, $VE_{INF}=10\%$)
282 and currently anticipated triggers for partial lockdown ($C_{max} = 350$), increasing vaccination rate
283 to 5000, 8000 or 11000 per day (0.23%, 0.36% and 0.46% of the population per day) would
284 substantially decelerate the expansion of a fourth wave in the spring of 2021 (**Fig 2b**) resulting in
285 616,676 (28%), 633,145 (29%) and 581,166 (27%) projected total infections, and 1753 (0.08%),
286 1766 (0.08%) and 1667 (0.076%) projected total deaths respectively. 5000 vaccination per day
287 would decrease the period of required lockdown during summer 2021 relative to 2000
288 vaccinations per day. 8000 vaccinations per day would blunt and delay the peak of the fourth
289 wave until late 2021: this would eliminate the need for further partial lockdown, though lack of
290 lockdown would allow slightly more infections by 2022 as a result.

291 A vaccine with less efficacy but the same mechanism ($VE_{SUSC}=50\%$, $VE_{SYMP}=10\%$,
292 $VE_{INF}=10\%$) would have comparable relative improvements at higher vaccination rates but
293 would save fewer lives and prevent fewer infections (**Fig 2c**). Under scenarios most compatible
294 with King county, cumulative infections would increase from 689,057 (31%) (**Fig 2b, orange**
295 **line**) to 969,161 (44%) (**Fig 2c, orange line**) while cumulative deaths would increase from 1806
296 (0.08%) to 2565 (0.12%). Recurrent partial lockdown is projected at all vaccination rates.

297 Similar vaccination-rate-dependent reductions in hospitalization and deaths were
298 projected assuming vaccines that prevented symptoms rather than infection among infected
299 people ($VE_{SUSC}=10\%$, $VE_{SYMP}=90\%$, $VE_{INF}=10\%$: **Fig 2d**, $VE_{SUSC}=10\%$, $VE_{SYMP}=50\%$,
300 $VE_{INF}=10\%$: **Fig 2e**), though numbers of cumulative infections were considerably higher due to

301 limited protection against secondary transmission. Under $VE_{SYMP}=90\%$ scenarios most
302 compatible with King county, cumulative infections and deaths are projected to be 785,870
303 (36%) and 1840 (0.084%) (**Fig 2d, orange line**). Recurrent partial lockdown is projected at all
304 vaccination rates.

305 For each scenario, strain replacement with the B.1.1.7 variant occurred rapidly during the
306 fourth wave between March and June of 2021 (**Fig 2f**).


307

308 *Reduction in COVID-19 cases and deaths, as well as time under partial lockdown due to*
309 *higher vaccine efficacy against infection.* We previously demonstrated that vaccines which
310 prevent transmission, either by preventing infection (VE_{SUSC}), or by preventing secondary
311 transmission despite infection (VE_{INF}), will decrease infections and deaths.³¹ With vaccines that
312 only reduce symptoms in infected people (VE_{SYMP}), achieving rapid herd immunity is contingent
313 on concurrent high VE_{INF} . In our current simulations with the B.1.1.7 variant, VE_{SUSC} negatively
314 correlates with infections, hospitalizations, deaths and number of days under partial lockdown;
315 VE_{SYMP} negatively correlates with total hospitalization and deaths; VE_{INF} slightly negatively
316 correlates with total infections and diagnosed cases (**Fig 2a**). However high efficacy against
317 infection is not sufficient to prevent a fourth wave or high numbers of deaths if C_{max} is high (**Fig**
318 **1b**) or vaccination rate is low (**Fig 2b**).

319

320 *Low case threshold for triggering partial lockdown and high vaccination rate: essential*
321 *variables to limit SARS-CoV-2 infections and deaths.* We include contour plots in which more
322 granular sampling across included ranges of vaccination rates and lockdown thresholds were

323



324 **Figure 3. High vaccination rate and low case threshold for triggering partial lockdown are the**
 325 **key variables for limiting total infections and deaths regardless of vaccine efficacy profile.**

326 Heat maps demonstrating joint effects of vaccination rate (x-axis) and case threshold for
 327 triggering partial lockdown (y-axis) are shown for four plausible vaccine profiles. **a.**
 328 $VE_{SUSC}=90\% / VE_{SYMP}=10\% / VE_{INF}=10\%$, **b.** $VE_{SUSC}=50\% / VE_{SYMP}=10\% / VE_{INF}=10\%$, **c.**
 329 $VE_{SUSC}=10\% / VE_{SYMP}=90\% / VE_{INF}=10\%$, **d.** $VE_{SUSC}=10\% / VE_{SYMP}=50\% / VE_{INF}=10\%$.
 330 Outcomes are total infections (top row), total deaths (middle row) and days under partial
 331 lockdown after vaccination initiation (bottom row). Increasing vaccination rate lowers infections
 332 and deaths across all scenarios. Increasing vaccination rate substantially lowers total days under
 333 lockdown, particularly when case threshold trigger for partial lockdown is low. Lowering case
 334 thresholds for triggering partial lockdown decreases total infections and deaths but results in
 335 higher number of days under partial lockdown in many scenarios. A decrease in VE_{SUSC} (**a** to **b**)
 336 results in more infections and deaths with only slight impact on time under lockdown. A
 337 decrease in VE_{SYMP} (**c** to **d**) results in more infections and deaths with only slight impact on time
 338 under lockdown. VE_{SUSC} provides a substantial reduction in infections but slight reduction in
 339 deaths relative to an equivalent VE_{SYMP} (**a** to **c** and **c** to **d**). All scenarios assume $C_{min}=25$ cases
 340 per 100,000 (2-week average) for relaxing partial lockdown and $\sigma_{min}=0.2$.

341


342 performed at four fixed vaccine scenarios, two of which would be compatible with results from
343 Moderna and Pfizer trials ($VE_{SUSC}=90\%$, $VE_{SYMP}=10\%$, $VE_{INF}=10\%$: **Fig 3a** or $VE_{SUSC}=10\%$,
344 $VE_{SYMP}=90\%$, $VE_{INF}=10\%$: **Fig 3b**) and two of which anticipate the possibility of less efficacy
345 after a single dose of these vaccines and/or less efficacy against novel variants ($VE_{SUSC}=50\%$,
346 $VE_{SYMP}=10\%$, $VE_{INF}=10\%$: **Fig 3c** or $VE_{SUSC}=10\%$, $VE_{SYMP}=50\%$, $VE_{INF}=10\%$: **Fig 3d**). These
347 scenarios capture vaccines which either effectively limit (**Fig 3a, c**) or do not effectively limit (**Fig**
348 **3b, d**) secondary transmission from vaccine recipients.

349 Key findings are that 1) decreasing C_{max} by several hundred cases may lower total
350 infections during 2021 by several hundred thousand and total deaths by several hundred, 2)
351 decreasing C_{max} by several hundred cases may increase total days under lockdown during 2021
352 by over a month (though approximately 100 of the total reported days under partial lockdown
353 have already been accrued during the third ongoing wave), 3) increasing the vaccination rate by
354 several thousand people per day may lower total infections by more than one hundred thousand,
355 total deaths by more than one hundred, and days under lockdown by two months, 4) increasing
356 the vaccination rate lowers cases and deaths under all scenarios, 5) increasing the vaccination
357 rate lowers total days under partial lockdown most significantly when C_{max} is low, 6) while
358 equivalent trends are noted across all four vaccine efficacies, high VE_{SUSC} rather than VE_{SYMP}
359 results in fewer infections but only slightly fewer deaths at equivalent C_{max} and vaccination rate,
360 and 7) higher vaccine efficacy (either against infection or symptoms) also results in fewer
361 infections and deaths at equivalent C_{max} and vaccination rates.

362

363 *Importance of high vaccination rate given viral variants with greater infectivity or more*
364 *frequent introduction of these variants into King County.* We performed equivalent analyses

365 but varied degrees of variant infectivity. With only a 35% increase in infectivity, increasing
 366 vaccination rate above 8000 per day prevented a fourth wave of infections and deaths (**Fig 4a**).
 367 Increasing variant infectivity to 75% resulted in a more severe fourth wave which could be
 368 dampened but not prevented with more rapid vaccination (**Fig 4b**). However, increasing the rate
 369 above 8000 per day lowered the time required under partial lockdown in this scenario.
 370



371
 372
 373
 374 **Figure 4. High vaccination rate, limits infections and deaths with either 35% or 75% more**
 375 **infectious novel SARS-CoV-2 variants.** Impact of varying vaccination rate on relevant
 376 outcomes. **a.** A 35% more infectious variant is assumed. High enough vaccination rate can
 377 prevent a fourth wave of infections and deaths. **b.** A 75% more infectious variant is assumed.
 378 Higher vaccination rate delays the fourth wave and lowers cumulative infection and peak death.
 379 All simulations assume $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ / $VE_{INF}=10\%$, $C_{max}=350$, and $C_{min}=25$
 380 and $\sigma_{min}=0.2$.

381 We next increased the daily introduction rate of contagious variants into King County
382 **(Sup fig 4)**, which only slightly increased the intensity of the fourth wave of cases and did not
383 impact the critical importance of high vaccination rate.

384

385 *Importance of high vaccine uptake to achieve benefits of high vaccination rate.* We performed
386 equivalent analyses but decreased or increased the percent of people in each age cohort receiving
387 a vaccine. Achieving 100% vaccine uptake would substantially limit the severity of fourth waves
388 particularly with vaccination rates exceeding 8000 per day **(Sup fig 5a)**. However, if uptake
389 decreased to 60%, higher peaks in daily deaths are projected during the fourth wave and the
390 benefit of rapid vaccination is almost completely lost **(Sup fig 5b)**.

391

392 *Importance of maintaining moderate social distancing during vaccine roll out and between*
393 *third and fourth waves of infection.* We performed equivalent analyses but increased **(Sup fig**
394 **6a)** or decreased **(Sup fig 6b)** the degree of social distancing when partial lockdown was relaxed.
395 We again noted that increased vaccination decreased cases and deaths under both scenarios.
396 Increasing the minimum social distancing maintained between waves of infection substantially
397 decreased total infections and allowed prevention of a fourth wave assuming high vaccination
398 rate **(Sup fig 6a)**.

399

400 Discussion

401

402 It is often stated that vaccines do not save lives, vaccinations do. Our modeling strongly
403 reinforces this point. High efficacy of vaccines against new more contagious variants, and in
404 particular their ability to block ongoing transmission rather than simply preventing symptoms,
405 will potentially prevent thousands of infections and save hundreds of lives in King County.³¹
406 However, the vaccination rate is of even greater importance and will determine the extent of a
407 fourth wave in the spring and summer of 2021 for all plausible vaccine efficacies. This wave has
408 the potential to be particularly lethal, given that a more contagious variant will predominate, but
409 may be quite limited if 8000 people (0.36% or 1 in 280 people) or more can be vaccinated daily.

410 Rapid vaccination will have the greatest absolute benefit in states such as Hawaii,
411 Vermont, Washington and Oregon that have maintained lower overall seroprevalence to date.
412 These states often employed more rapid triggering of partial lockdown during recent waves of
413 SARS-CoV-2 infection. Because a higher proportion of people are still susceptible in these
414 states, they are particularly vulnerable to contagious variant strains. A larger percentage of
415 people will in turn need to be vaccinated to reach herd immunity. Aside from lowering
416 infections, hospitalizations and deaths, more rapid vaccination will also decrease the total
417 number of days under partial lockdown.

418 Our model projects that with the new more infectious variants, higher case thresholds for
419 triggering partial lockdown will result in greater numbers of total infections and deaths per
420 capita.¹⁸ Even with the current consensus variant, this projection has been observed during prior
421 waves of infection: multiple states in the northern plains and southwest recently endured a severe
422 third wave relative to Washington state. In these states, widespread vaccination may contribute

423 relatively less to generation of herd immunity, which instead will be reached in part from a high
424 number of cases. This conclusion is most relevant if existing vaccines retain efficacy for both
425 variants and if prior infection is cross-protective against new variants. Some concern for waning
426 immunity or lack of cross-variant protection exists based on recent experience in Manaus where
427 a severe wave of infection is ongoing despite high pre-existing seroprevalence.⁴²

428 Our simulations suggest that lowering the case threshold for partial lockdown will most
429 significantly decrease the number of total infections in 2021 if coupled with a high vaccination
430 rate. This is because the high infectivity of B.1.1.7 and other emerging variants will make fourth
431 waves severe, even if partial lockdown is initiated relatively early. The current harrowing
432 experiences in London and Manaus are consistent this projection. Lowering the case threshold
433 for partial lockdown will decrease total deaths under all scenarios assuming high efficacy
434 vaccines because this strategy will allow more time to vaccinate the elderly.

435 We demonstrate that increasing physical distancing and masking between third and
436 fourth waves (increasing minimum SD in the model) will also decrease cases and deaths.
437 Strategies for pandemic management during 2021, both during and between waves, should
438 mirror and improve upon those taken during the early months of the pandemic: widespread
439 masking with N95 masks in crowded environments,¹⁹ avoidance of large crowds, and a focus on
440 improved ventilation in high-risk indoor environments. Prevalent use of rapid, inexpensive
441 testing could aid in efficient contact tracing and case “cluster busting”.²⁰ Yet, these measures are
442 likely to be insufficient if known super-spreader environments such as crowded restaurants and
443 bars are also not closed for a short period of time. Unfortunately, lowering the case threshold for
444 partial lockdown may result in a slightly longer time under lockdown overall in 2021, though
445 some of this time has already been accrued.

446 Importantly, the key drivers of health-related outcomes hold under various vaccine
447 profiles including lower overall vaccine efficacy, or a shift from protection against infection to
448 protection against symptoms, both of which are possible with emerging new variants. These
449 scenarios would lead to more overall infections and deaths, and would only add urgency to the
450 need to vaccinate as quickly as possible and set low case thresholds for partial lockdown. We
451 also demonstrate that vaccine uptake is crucial. If only 60% of the elderly cohort accepts a
452 vaccine, then a severe fourth wave with requirement for partial lockdown is likely.

453 A similar conclusion can be made for variants that increase infectivity by 75%, as
454 appears to be possible with the South African B.1351 lineage.¹⁶ In this scenario, avoidance of a
455 fourth wave may unfortunately not be possible. However, rapid vaccination will blunt and delay
456 the fourth wave, perhaps avoiding the requirement for partial lockdown. Maintaining high levels
457 of masking and physical distancing between waves is crucial under this circumstance.

458 The current Pfizer and Moderna mRNA vaccines have extremely high efficacy against
459 disease but require two doses.^{35,36} Initial data from the Moderna trial suggests the possibility of
460 >50% protection against asymptomatic infection following the first dose, though confirmation is
461 required in studies not including a second dose. The Johnson and Johnson vaccine is 69%
462 effective and is given as a single dose.³⁸ Our results highlight the critical importance of
463 evaluating single dose regimens because doubling the rate of vaccination assuming equivalent
464 efficacy could prevent thousands of infections, hundreds of deaths and dozens of days under
465 partial lockdown in King County alone and could also be the factor which eliminates a
466 meaningful surge of cases in spring 2021.

467 By simulating the model without introducing B.1.1.7, we provide a negative control to
468 assess the additional damage that is expected due its higher infectivity. Unfortunately, the new

469 variant is likely to contribute to excess infections and deaths. Vaccination scenarios which would
470 have achieved herd immunity quickly enough to prevent a fourth wave with the current dominant
471 variant will fail to do so with B.1.1.7. The timing and severity of the fourth wave is nevertheless
472 difficult to project based on uncertainty of variant infectivity, current prevalence of contagious
473 variants in the community, possible loss of vaccine efficacy against new variants and uncertainty
474 regarding adherence to masking and physical distancing in the upcoming months.

475 While our model is calibrated closely to King County Washington, it allows various case
476 thresholds for partial lockdown and distribution rates. To this end, its projections are relevant for
477 regions with lower and higher seroprevalence, and it is useful for understanding future different
478 case trajectories in multiple states.

479 However, several limitations are notable. Our contact network is stratified by age and not
480 race or profession and therefore is likely to miss important heterogeneities in transmission risk.
481 We only assume initial vaccine allocation predominately to the elderly and a subset of younger
482 health care workers to match current plans. While we make general projections about single
483 versus double vaccination, we do not consider the specifics of vaccine scheduling and delays in
484 accrued protection against infection.

485 We also assume no waning immunity following natural infection or vaccination, and do
486 not include the possibility of added protection in people who are first infected and then
487 vaccinated. Based on existing data demonstrating prolonged antibody response after vaccination
488 and natural infection,^{43,44} we believe that this issue can be neglected over the time intervals we
489 model. Rapid loss of immunity would enhance the need to vaccinate quickly. Careful
490 surveillance for SARS-CoV-2 re-infection, as well as viral antigenic drift, is needed urgently and

491 will dictate the need for re-vaccination. Rapid institution of partial lockdown and vaccination
492 will remain the two key strategies to limit deaths and number of days under lockdown.

493 Finally, we project a 2 to 3-month delay until new variant cases surge. This is based on
494 the fact that among sequenced viruses in the United States, new variants appear relatively
495 uncommon at this stage representing fewer than 0.5% of sequenced viruses.¹⁸ However, if
496 current estimates are misleadingly low, then a wave of infections can be expected sooner when a
497 lower proportion of the population has been vaccinated and/or infected.

498 In conclusion, we project that despite considerable uncertainty about the timing and
499 severity of variant waves in the United States, rapid vaccine distribution and low case threshold
500 for triggering partial lockdown are the two critical components to save the most lives.

501 **Methods.**

502

503 ***King Country transmission model.*** We modified a previously developed deterministic
504 compartment model,⁴⁵ which captures the epidemic dynamics in King County, WA between
505 January 2020 and October 2020 and projects the trajectory of the local pandemic through the end
506 of 2021 in the absence and presence of vaccines³¹. Vaccination is simulated with a starting date
507 of January 1, 2021. We include the possibility of infection with a new variant with a potentially
508 higher infectivity, which is assumed to already be circulating at undetectable levels and is also
509 imported continuously throughout the coming months.

510 Our mathematical model is an extension of an SIR model in which each state variable (or
511 compartment) can be stratified by age (4 compartments, children <20, young adults 20-40, adults
512 40-70, and seniors >70), vaccine status (yes or no), and infecting strain (current or B117 strain).
513 Thus, state variables are tensors $X(a, V, q)$ with dimensions for age group, vaccine status, and
514 infecting strain. We include compartments for susceptible, exposed, pre-symptomatic,
515 asymptomatic, symptomatic, hospitalized, and deceased. We also include separate compartments
516 for diagnosed cases of each infected type both for the original model fitting to cases but also
517 because diagnosed cases may behave differently from individuals who do not know their
518 infection status. The model schematic and illustrations of case-dependent social distancing and
519 vaccine roll-out are shown in **Supp fig 1**. All mathematical details are presented in the
520 **Supplementary Information.**

521

522 ***Modeling vaccination and case-dependent partial lockdowns.*** Vaccination is modeled as a
523 constant distribution of vaccines r (doses per day) that are given first to at 80% to seniors (70+)

524 and 20% to adults. Children are not vaccinated. When a maximum coverage (V_{max}) is reached in
525 the senior group, distribution continues to adults.

526 Vaccines can work by several mechanisms simultaneously. They can completely block
527 infection (VE_{SUSC} – reducing the number of susceptible individuals), block symptomatic disease
528 (VE_{SYMP} – adjust the fraction of infections that are symptomatic vs asymptomatic), and/or
529 decrease the possibility of onward transmission after infection (VE_{INF} – reducing the force of
530 infection). Each vaccine efficacy ranges from 0-1.

531 To attempt to accurately model societal or governmental responses to pandemic surges,
532 we include a time-dependent term that reduces contacts when cases reach a certain point. This
533 term $\sigma(a, t)$ varies from 0, indicating pre-pandemic levels of societal interactivity and no
534 masking, to 1, indicating complete lockdown with no interactions (**Supp Fig 1b**). When two-
535 week number of diagnosed cases per 100,000 people rises above C_{max} , a “partial-lockdown”
536 ($\sigma(a, t) \rightarrow \sigma_{PL}$) is mandated (**Supp Fig 1b**). Partial lockdown is defined by an enforced social
537 distancing of $\sigma_{PL}=0.6$ in the 3 younger age cohorts and $\sigma_{PL}=0.8$ in seniors (≥ 70 years). When
538 cases drop below a relaxation threshold C_{min} , $\sigma(a, t)$ is lowered gradually from σ_{PL} to $\sigma_{min}(a)$
539 at a rate of 10% reduction in $\sigma(a, t)$ every two weeks that cases stay below the threshold.
540 Notably, minimum distancing of seniors is still 20% higher than in younger cohorts.

541 Several other explored parameters (see **Supp figs 4-7** include the infectivity of the new
542 variant, the rate of imports of the new strain, and variation in minimal social distancing.

543

544 **Model simulation.** Ordinary differential equations are used to simulate the model using *lsoda* in

545 R.

546

547 **Model calibration and parameterization.** Model calibration and parameterization was performed
548 in Ref. ³¹. This involved fitting the model to Diagnosed Cases, Hospitalizations, and Deaths from
549 Department of Health data in King County Washington. Age proportions and age structured
550 contact matrices were inferred from local demographic and contact data. All initial conditions
551 and parameters for the model can be found in **Sup Table 2**.

552 **Global sensitivity analysis.** We performed a comprehensive exploration of vaccination rate,
553 mechanisms, and case levels for triggering and releasing lockdown: all combinations of all
554 parameters in Table 1. 12 outcomes quantifying societal and public health were recorded (see
555 **Sup Fig 2**) for each simulation. Then, correlation and clustering analyses were performed by
556 calculating Spearman correlations among outcomes and between variables and outcomes using
557 the Seaborn package in Python.


558 **Code.** All R code for model simulations are freely available at
559 www.github.com/FredHutch/COVID_modeling. Custom plotting scripts in R and Python are
560 available upon request.

561 **Table 1. Sensitivity analysis parameters.**


Variable	Definition	Values
Vaccination rate (r)	Rate of vaccination per day (assuming requirement for two doses per Moderna and Pfizer vaccines)	2000, 5000, 8000, 11000
VE_{SUSC}	Vaccine efficacy against infection: the % of infections that are completely blocked	10, 50, 90
VE_{SYMP}	Vaccine efficacy against symptoms: the % of breakthrough infections in vaccine recipients that are reduced to asymptomatic infections	10, 50, 90
VE_{INF}	Vaccine efficacy against infectivity: the % of prevented secondary transmissions from infected vaccine recipients	10, 50, 90
Lockdown case threshold (C_{max})	The number of cases over a 14-day period per 100,000 people at which a lockdown is instituted	200, 350, 500, 650
Lockdown release case threshold (C_{min})	The number of cases over a 14-day period per 100,000 people at which a lockdown is released	20, 60, 100

562


563



B Dynamic social distancing - case based partial lockdowns




C Vaccine roll out - constant accrual rate r (per day), age ordered




564
565
566
567
568

Supplementary figure 1. Mathematical model schematic. a. Model structure, b. Dynamic social distancing framework, c. Vaccination rollout plan.




569
570
571
572
573
574
575

Supplementary figure 2. Correlations among model outcomes. **a.** Spearman correlation coefficients between model outcomes from 3888 simulations, **b.** Spearman correlation coefficients between model outcomes excluding all $C_{max}=650$ scenarios where partial lockdown does not occur during the third wave of infection.




576
577
578
579
580
581
582

Supplementary figure 3. Individual simulations with projections of outcomes. Dot plots represent relationship between variables listed on the x- and y-axes. Each dot represents a single simulation with a unique parameter set. Line diagrams represent density plots for a given outcome projected on the x-axis.



583
 584
 585
 586
 587
 588
 589
 590
 591
 592


Sup fig 4. High vaccination rate limits infections and deaths with slow or rapid introduction of a 55% more infectious SARS-CoV-2 variant into King County. a. An import rate of 2.5 cases per day is assumed. **b.** An import rate of 10 cases per day is assumed. In both scenarios, a higher vaccination rate delays the fourth wave and lowers cumulative infection and peak death. All simulations assume $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ / $VE_{INF}=10\%$, $C_{max}=350$. and $C_{min}=25$.



593
594
595

596 **Sup fig 5. High vaccination rate limits infections and deaths only with sufficient vaccine**
 597 **uptake.** Impact of varying vaccination rate on relevant outcomes. **a.** 100% of each age cohort is
 598 assumed to receive the vaccine. High enough vaccination rate can prevent a fourth wave. Higher
 599 vaccination rate prevents a large fourth wave **b.** 60% of each age cohort is assumed to receive the
 600 vaccine. Higher vaccination rate delays but does not blunt the fourth wave and lowers
 601 cumulative infection and peak death. All simulations assume $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ /
 602 $VE_{INF}=10\%$, $C_{max}=350$ and $C_{min}=25$.

603
604



605
606
607
608
609
610
611
612
613
614
615

Sup fig 6. High vaccination rate limits infections and deaths to a greater degree when higher social distancing is maintained between partial lockdown periods. Impact of varying vaccination rate on relevant outcomes. **a.** A minimum 30% social distancing value is assumed. High enough vaccination rate can almost prevent a fourth wave. **b.** A minimum 10% social distancing value is assumed. Higher vaccination rate delays but does not prevent the fourth wave and lowers cumulative infection and peak death. All simulations assume $VE_{SUSC}=90\%$ / $VE_{SYMP}=10\%$ / $VE_{INF}=10\%$, $C_{max}=350$. and $C_{min}=25$.

616 **References**

- 617
- 618 1 <https://coronavirus.jhu.edu>.
- 619 2 de Lima, C. V. C. *et al.* Effects of quarantine on mental health of populations affected by
620 Covid-19. *J Affect Disord* **275**, 253-254, doi:10.1016/j.jad.2020.06.063 (2020).
- 621 3 Duan, L. *et al.* An investigation of mental health status of children and adolescents in
622 china during the outbreak of COVID-19. *J Affect Disord* **275**, 112-118,
623 doi:10.1016/j.jad.2020.06.029 (2020).
- 624 4 Wright, H. M. *et al.* Pandemic-related mental health risk among front line personnel. *J*
625 *Psychiatr Res*, doi:10.1016/j.jpsychires.2020.10.045 (2020).
- 626 5 [https://www.cdc.gov/vaccines/imz-managers/downloads/Covid-19-Vaccination-Program-](https://www.cdc.gov/vaccines/imz-managers/downloads/Covid-19-Vaccination-Program-Interim_Playbook.pdf)
627 [Interim_Playbook.pdf](https://www.cdc.gov/vaccines/imz-managers/downloads/Covid-19-Vaccination-Program-Interim_Playbook.pdf).
- 628 6 Huang, C. *et al.* 6-month consequences of COVID-19 in patients discharged from
629 hospital: a cohort study. *Lancet* **397**, 220-232, doi:10.1016/S0140-6736(20)32656-8
630 (2021).
- 631 7 [https://www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-](https://www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf)
632 [COVID-19-Response-and-Pandemic-Preparedness.pdf](https://www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf).
- 633 8 Ferretti, L. *et al.* Quantifying SARS-CoV-2 transmission suggests epidemic control with
634 digital contact tracing. *Science* **368**, doi:10.1126/science.abb6936 (2020).
- 635 9 Fisman, D. N., Greer, A. L. & Tuite, A. R. Bidirectional impact of imperfect mask use on
636 reproduction number of COVID-19: A next generation matrix approach. *Infect Dis Model*
637 **5**, 405-408, doi:10.1016/j.idm.2020.06.004 (2020).
- 638 10 Howard, J. *et al.* An evidence review of face masks against COVID-19. *Proc Natl Acad*
639 *Sci U S A* **118**, doi:10.1073/pnas.2014564118 (2021).

- 640 11 Goyal, A., Reeves, D. B., Cardozo-Ojeda, E. F., Schiffer, J. T. & Mayer, B. T. Wrong
641 person, place and time: viral load and contact network structure predict SARS-CoV-2
642 transmission and super-spreading events. *medRxiv*, 2020.2008.2007.20169920,
643 doi:10.1101/2020.08.07.20169920 (2020).
- 644 12 <https://covid19-projections.com/us>.
- 645 13 <https://covidtracking.com>.
- 646 14 Volz, E. *et al.* Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from
647 linking epidemiological and genetic data. *medRxiv*, 2020.2012.2030.20249034,
648 doi:10.1101/2020.12.30.20249034 (2021).
- 649 15 [https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
650 [manaus-preliminary-findings/586](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586).
- 651 16 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory
652 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in
653 South Africa. *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640
654 (2020).
- 655 17 Volz, E. *et al.* Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on
656 Transmissibility and Pathogenicity. *Cell* **184**, 64-75.e11, doi:10.1016/j.cell.2020.11.020
657 (2021).
- 658 18 Galloway, S. E. *et al.* Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States,
659 December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 95-99,
660 doi:10.15585/mmwr.mm7003e2 (2021).
- 661 19 Goyal, A., Reeves, D. B., Cardozo Ojeda, E. F., Mayer, B. T. & Schiffer, J. T. Slight
662 reduction in SARS-CoV-2 exposure viral load due to masking results in a significant

- 663 reduction in transmission with widespread implementation. *medRxiv*,
664 2020.2009.2013.20193508, doi:10.1101/2020.09.13.20193508 (2020).
- 665 20 Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time for
666 COVID-19 surveillance. *medRxiv*, 2020.2006.2022.20136309,
667 doi:10.1101/2020.06.22.20136309 (2020).
- 668 21 Davies, N. G. *et al.* Estimated transmissibility and severity of novel SARS-CoV-2
669 Variant of Concern 202012/01 in England. *medRxiv*, 2020.2012.2024.20248822,
670 doi:10.1101/2020.12.24.20248822 (2020).
- 671 22 Chaudhry, R., Dranitsaris, G., Mubashir, T., Bartoszko, J. & Riazi, S. A country level
672 analysis measuring the impact of government actions, country preparedness and
673 socioeconomic factors on COVID-19 mortality and related health outcomes.
674 *EClinicalMedicine* **25**, 100464, doi:10.1016/j.eclinm.2020.100464 (2020).
- 675 23 <https://www.covidlive.co.uk>.
- 676 24 Yang, W., Kandula, S. & Shaman, J. Simulating the impact of different vaccination
677 policies on the COVID-19 pandemic in New York City. *medRxiv*,
678 2021.2001.2021.21250228, doi:10.1101/2021.01.21.21250228 (2021).
- 679 25 Matrajt, L., Eaton, J., Leung, T. & Brown, E. R. Vaccine optimization for COVID-19:
680 who to vaccinate first? *medRxiv*, 2020.2008.2014.20175257,
681 doi:10.1101/2020.08.14.20175257 (2020).
- 682 26 Buckner, J. H., Chowell, G. & Springborn, M. R. Dynamic Prioritization of COVID-19
683 Vaccines When Social Distancing is Limited for Essential Workers. *medRxiv*,
684 2020.2009.2022.20199174, doi:10.1101/2020.09.22.20199174 (2020).

- 685 27 Grundel, S. *et al.* How to coordinate vaccination and social distancing to mitigate SARS-
686 CoV-2 outbreaks^{*}. *medRxiv*, 2020.2012.2022.20248707,
687 doi:10.1101/2020.12.22.20248707 (2020).
- 688 28 Bertsimas, D. *et al.* Optimizing Vaccine Allocation to Combat the COVID-19 Pandemic.
689 *medRxiv*, 2020.2011.2017.20233213, doi:10.1101/2020.11.17.20233213 (2020).
- 690 29 Matrajt, L. *et al.* Optimizing vaccine allocation for COVID-19 vaccines: critical role of
691 single-dose vaccination. *medRxiv*, 2020.2012.2031.20249099,
692 doi:10.1101/2020.12.31.20249099 (2021).
- 693 30 Swan, D. A. *et al.* COVID-19 vaccines that reduce symptoms but do not block infection
694 need higher coverage and faster rollout to achieve population impact. *medRxiv*,
695 2020.2012.2013.20248142, doi:10.1101/2020.12.13.20248142 (2020).
- 696 31 Swan, D. A. *et al.* Vaccines that prevent SARS-CoV-2 transmission may prevent or
697 dampen a spring wave of COVID-19 cases and deaths in 2021. *medRxiv*,
698 2020.2012.2013.20248120, doi:10.1101/2020.12.13.20248120 (2020).
- 699 32 Grant, A. & Hunter, P. R. Immunisation, asymptomatic infection, herd immunity and the
700 new variants of COVID 19. *medRxiv*, 2021.2001.2016.21249946,
701 doi:10.1101/2021.01.16.21249946 (2021).
- 702 33 Bracis, C. *et al.* Widespread testing, case isolation and contact tracing may allow safe
703 school reopening with continued moderate physical distancing: A modeling analysis of
704 King County, WA data. *Infectious Disease Modelling* **6**, 24-35,
705 doi:<https://doi.org/10.1016/j.idm.2020.11.003> (2021).

- 706 34 Halloran, M. E., Haber, M., Longini, I. M. & Struchiner, C. J. Direct and indirect effects
707 in vaccine efficacy and effectiveness. *Am J Epidemiol* **133**, 323-331,
708 doi:10.1093/oxfordjournals.aje.a115884 (1991).
- 709 35 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*
710 *Engl J Med*, doi:10.1056/NEJMoa2035389 (2020).
- 711 36 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*
712 *Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 713 37 [https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3)
714 [demonstrates-893-efficacy-uk-phase-3.](https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3)
- 715 38 [https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-](https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial)
716 [candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial.](https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial)
- 717 39 [https://medium.com/wagovernor/inslee-announces-state-plan-for-widespread-vaccine-](https://medium.com/wagovernor/inslee-announces-state-plan-for-widespread-vaccine-distribution-and-administration-62196dcf5ecf)
718 [distribution-and-administration-62196dcf5ecf.](https://medium.com/wagovernor/inslee-announces-state-plan-for-widespread-vaccine-distribution-and-administration-62196dcf5ecf)
- 719 40 [http://www.snohd.org/civicalerts.aspx?AID=484.](http://www.snohd.org/civicalerts.aspx?AID=484)
- 720 41 [https://www.kingcounty.gov/depts/health/covid-19/data/daily-summary.aspx.](https://www.kingcounty.gov/depts/health/covid-19/data/daily-summary.aspx)
- 721 42 Sabino, E. C. *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high
722 seroprevalence. *Lancet*, doi:10.1016/S0140-6736(21)00183-5 (2021).
- 723 43 Widge, A. T. *et al.* Durability of Responses after SARS-CoV-2 mRNA-1273
724 Vaccination. *N Engl J Med* **384**, 80-82, doi:10.1056/NEJMc2032195 (2021).
- 725 44 Choe, P. G. *et al.* Antibody Responses 8 Months after Asymptomatic or Mild SARS-
726 CoV-2 Infection. *Emerg Infect Dis* **27**, doi:10.3201/eid2703.204543 (2020).
- 727 45 Bracis, C. *et al.* Widespread testing, case isolation and contact tracing may allow safe
728 school reopening with continued moderate physical distancing: a modeling analysis of

729 King County, WA data. *medRxiv*, 2020.2008.2014.20174649,

730 doi:10.1101/2020.08.14.20174649 (2020).

731

Supplementary Information: COVID SA

*DB Reeves**, *C Bracis**, *DA Swan*, *M Moore*, *D Dimitrov***, *JT Schiffer***

*,** = equal contribution

In this supplementary information we include details of the extended SIR model. All code is freely available at www.github.com/FredHutch/COVID_modeling.

To model SARS-CoV-2 epidemiological dynamics we have applied a dynamical systems approach which uses an SIR model extended in several key ways. In general each state variable is now a tensor whose dynamics are given by its properties, distinguished as age group a , vaccination status V , and depending on the infecting strain q . The model extensions are detailed in Table S1 and a schematic cartoon is provided in Fig S1.

variable	values	definition
a	[0-19,20-49,50-69,70+]	age group (years)
V	[0, 1]	vaccination status, 1 = vaccinated
q	[current, B117]	infecting strain
σ_t	continuous, time-dependent	% reduction in contacts due to social/physical distancing

Table S1: Variables describing extensions to SIR model.

Force of infection. Perhaps the most important equation for the model summarizing the dynamics is the ‘force of infection’. Here we show the value of the force of infection for each subset of state variables. The force of infection depends on the state of the infected individual (X) and the strain-specific infectivity $\beta_X(q)$. It also depends on a time-dependent reduction in contacts mediated by social/physical distancing σ_t . Finally, we use the empirically derived contact matrix to adjust the force of infection on a certain age group from transmitters in each other age groups (denoted by a_T , and calculated using the adjacency matrix $\mathcal{A}(a, a_T)$). Finally, we have the force of infection for an individual in age group a , exposed to strain q , with vaccination status V , and with ongoing social distancing level σ_t :

$$\lambda[a, V, q|\sigma(a, t)] = (1 - \text{VE}_{\text{INF}}(V)) \sum_{a_T} \frac{\mathcal{A}(a, a_T)}{N(a_T)} \sum_{X \in \mathcal{X}} [1 - \sigma(a, t)] \beta_X(q) X(a_T, V, q) \quad (\text{S1})$$

where $\mathcal{X} = \{A, P, I, C_A, C_I\}$ is the set of all potentially infectious states. Note it is assumed that hospitalized individuals do not contribute to transmission ($\beta_H = 0$). Naturally, susceptible, exposed, recovered, and deceased individuals also do not contribute to ongoing infection.

The total number of individuals (across age, vaccination, and strain) in each compartment can then be calculated as a sum over the variables as

$$X = \sum_{a, V, q} X(a, V, q) \quad (\text{S2})$$

Assumptions on asymptomatic infection. We assume that 20% of infections are asymptomatic and that asymptomatic people are as infectious as symptomatic individuals but missing the highly infectious pre-symptomatic phase. As a result, the relative infectiousness of individuals who never develop symptoms is 56% of the overall infectiousness of individuals who develop symptomatic COVID-19. This conservative estimate falls between the 35% relative infectiousness estimated in recent review based on 79 studies¹ and the current best estimate of 75% suggested by the CDC in their COVID-19 pandemic planning scenarios.

Dynamic social distancing. An attribute that sets our model apart from most others is a notion of dynamical social distancing related to the current diagnosed cases. We include a time-varying, age-stratified vector $\sigma(a, t)$ that governs social distancing (non-pharmaceutical interventions) including reduced contacts through personal choices and/or mandated partial lockdowns, as well as reductions in exposure contacts due to mask wearing or physical distancing. $\sigma(a, t)$ varies from 0, indicating pre-pandemic levels of societal interactivity and no masking, to 1, indicating complete lockdown with no interactions. This function is parameterized by 4 values: the maximum C_{max} and minimum C_{min} number of cases and the partial-lockdown and reopened social distancing values $\sigma_{PL}(a)$ and $\sigma_{min}(a)$ (see Supp Fig 1B). Thus we have

$$\sigma(a, t) = \begin{cases} \sigma_{PL}(a) & \langle C(t) \rangle_T > C_{max} \\ \sigma_{PL}(a) - 0.1T & \langle C(t) \rangle_T < C_{min} \\ \sigma_{min}(a) & \sigma_{max}(a) - 0.1T < \sigma_{min}(a) \end{cases} \quad (S3)$$

where the time average of cases $\langle C(t) \rangle_T$ is taken over $T = 2$ week intervals in the current simulation. Thus, the system triggers lockdown if the average cases rises over the max threshold and distancing immediately becomes $\sigma_{PL}(a)$ which is 40% of prepandemic levels in non-seniors and 20% in seniors. Then, once cases drop below the release threshold C_{min} , 10% of the distancing is removed every T weeks until reaching the minimum social distancing $\sigma_{min}(a)$. This value is not necessarily zero because we expect persistent features such as masking, work from home and avoidance of large social gatherings will continue to limit the number of interpersonal contacts relative to pre-pandemic levels.

Vaccination mechanisms. The possibility of vaccination is further complicated by inclusion of 3 mechanisms. The vaccine can completely block infection (VE_{SUSC}), adjust the fraction of infections that are symptomatic (VE_{SYMP}), and/or decrease the possibility of onward transmission after infection (VE_{INF}). Each vaccine efficacy ranges from 0-1.

The number of individuals in each age group $N(a)$ is calculated at each step as

$$N(a) = \sum_{V, q} \sum_{X \in \mathcal{X}} X(a, V, q) \quad (S4)$$

where $\mathcal{X} = \{S, E, A, P, I, C_A, C_I, H, R\}$ is all non-deceased states. We also sum over the vaccinated and unvaccinated individuals, and over infecting strains.

¹Buitrago-Garcia *et al.* PLOS Medicine (2020) doi:10.1371/journal.pmed.1003346.

Vaccination program. The vaccination program is implemented to best-mimic the current practice of vaccinating mostly elderly first, and then adult age groups, but never children. Vaccination distribution follows a daily rate r . Thus we allow 80% of vaccines to go to elderly each day $S(a = 70+, V = 1) = 0.8rt$ and the remaining 20% to adults $S(20 < a < 70, V = 1) = 0.2rt$. We set a maximum coverage V_{max} that roughly models vaccine uptake and compliance. Once the coverage is reached in the elderly, all vaccines are distributed to adults.

The whole set of equations thus is

$$\begin{aligned}
 \dot{\mathbf{S}} &= - \sum_q \lambda[a, V, q | \sigma(a, t)] (1 - VE_{SUSC}(V)) \mathbf{S} \\
 \dot{\mathbf{E}} &= \lambda[a, V, q | \sigma(a, t)] (1 - VE_{SUSC}(V)) \mathbf{S} - \gamma \mathbf{E} \\
 \dot{\mathbf{A}} &= [1 - \pi(a)(1 - VE_{SYMP}(V))] \gamma \mathbf{E} - (\rho_A + \Delta_A) \mathbf{A} \\
 \dot{\mathbf{P}} &= \pi(a)(1 - VE_{SYMP}(V)) \gamma \mathbf{E} - (\zeta + \Delta_P) \mathbf{I} \\
 \dot{\mathbf{I}} &= \zeta \mathbf{P} - \Delta_I(a, t) \mathbf{I} - [1 - \mu(a)] \eta_I(a) \mathbf{I} - \mu(a) \rho_I \mathbf{I} \\
 \dot{\mathbf{H}} &= [1 - \mu(a)] \eta_I(a) \mathbf{I} + \eta_C(a) \mathbf{C}_I - \rho_H \mathbf{H} - \delta \mathbf{H} \\
 \dot{\mathbf{F}} &= \delta_H \mathbf{H} + \delta_I(a) \mathbf{I} \\
 \dot{\mathbf{R}} &= \rho_A [\mathbf{A} + \mathbf{C}_A] + \mu(a) \rho_I \mathbf{I} + \rho_C(a) \mathbf{C}_I + \rho_H \mathbf{H}
 \end{aligned} \tag{S5}$$

and equations for diagnosed cases follow

$$\begin{aligned}
 \dot{\mathbf{C}}_A &= \Delta_A \mathbf{A} - \rho_A \mathbf{C}_A \\
 \dot{\mathbf{C}}_I &= \Delta_P \mathbf{P} + \Delta_I(a, t) \mathbf{I} - \eta_C(a) \mathbf{C}_I - \rho_C \mathbf{C}_I
 \end{aligned} \tag{S6}$$

Comments on diagnosed cases. In addition to the main set of differential equations (Eq. S5), we also track the equations that govern the accumulating diagnosed cases (C_X , Eq. S6). Diagnosed cases can reenter the main equation set above because of hospitalizations due to diagnosed cases. We use the total diagnosed cases $C = C_A + C_I$ to fit caseload data. A nuance is that diagnosis rates $\Delta_X(a, t)$ are explicitly time dependent, which is used to incorporate data on number of individuals in each age group that are seeking testing. Importantly, diagnosed individuals may behave differently, so they are separated in the model for this reason too.

Initial conditions and model parameters. We use the state of the pandemic in October 2020 as derived in our prior publication² to initialize and parameterize the simulations in this manuscript.

Initial conditions are tabulated in Table S2. Fixed parameters are tabulated in Table S3, and estimated parameters are tabulated in Table S4.

²Swan, D. A. et al. Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021. medRxiv 133, 323–57 (2020)

State	Initial condition			
	Children	Young Adults	Adults	Seniors
S	471690	950078	493341	169429
E	1175	1973	925	297
A	469	634	300	107
P	624	932	423	139
I	1763	2260	1139	509
C_A	217	805	248	5
C_I	43	158	46	0.73
H	3	25	34	85
R	26183	40004	18032	5115
F	0	19	162	609

Table S2: Initial conditions, no vaccinated individuals and no new strain, i.e. $V = 0$ and q =current for all entries.

Variable	Value	Definition	Reference
θ	7 days	Duration of infectious period	Cevik et al. Lancet Microbe 2021
γ	1/3 day ⁻¹	Inverse of first part of estimated incubation period, the rate of transition from exposed to next stage of infection (either presymptomatic or asymptomatic)	McAloon et al. BMJ 2020, Lauer et al. Annals Int Med 2020
ζ	1/2 day ⁻¹	Inverse of second part of incubation period progression from pre-symptomatic to symptomatic infection	Qin et al. Science Adv
π	0.8	Proportion of infections that are symptomatic infection.	Buitrago-Garcia et al. PLOS Medicine 2020
η_I	1/6 day ⁻¹	Hospitalization rate from symptomatic state, from median days to hospitalization	CDC
ρ_H	1/14 day ⁻¹	Recovery rate from hospitalized	CDC
δ_I	1/24 day ⁻¹	Fatality rate from symptomatic, inverse of median days from symptom onset to death	CDC
δ_H	1/20 day ⁻¹	Fatality rate from hospitalized, this assumes no overwhelming of healthcare system ICU capacity	CDC

Table S3: Fixed parameters.

variable	value	definition
$\beta^*(q)$	0.21 person ⁻¹ day ⁻¹	Infectivity by SARS-CoV-2 strain
β_{C_A}, β_{C_I}	$0.63\beta^*$	Infectivity of diagnosed cases, less than undiagnosed
$\Delta_X(a)$	0.015, 0.042, 0.026, 0.0011 day ⁻¹	Diagnosis rates from each age group, currently each state (presymptomatic, asymptomatic, symptomatic) has the same diagnosis rate
$\eta_I(a), \eta_C(a)$	$f_H(a) \times [0.02, 0.046, 0.028, 0.05]$ day ⁻¹	Hospitalization rate from severe cases, uses a monthly smoothed average of the fraction of cases f_H resulting in hospitalization from WA Department of Health
β_A, β_I	β^*	Infectivity of asymptomatic and symptomatic individuals are identical.
β_P	$2.75\beta^*$	Infectivity of presymptomatic individuals, calculated from result that $f_P=44\%$ of infections are presymptomatic $\beta_P = \frac{f_P}{1-f_P}\theta\zeta$
ρ_I, ρ_A, ρ_C	1/7 day ⁻¹	Recovery rate from symptomatic, asymptomatic, and diagnosed cases that are mild and do not require hospitalization; calculated as $1/\theta$
$\delta_H(a)$	$1/f_H \times [0.025 \times 10^{-4}, 5.5 \times 10^{-3}]$ day ⁻¹	Fatality rate from hospitalized cases, uses the case fatality ratio from the WA department of health as well as the fraction

Table S4: Estimated and inferred parameters.